Fox Chase researchers give mutants another chance

February 11, 2009

Researchers at Fox Chase Cancer Center have demonstrated that it might be possible to treat genetic diseases, including some forms of cancer, by "rescuing" the misshapen, useless proteins produced by some mutant genes.

In the current issue of the Journal of Biological Chemistry, available online now, researchers detail how they were able to restore the function of a mutant human gene in a yeast model of disease by manipulating the available amounts of a so-called chaperone protein, named Hsp70, which helps amino acid chains fold into their proper protein form.

"In some cases, despite a mutation, it is possible to coax a misfolded protein back into a functional conformation," says the paper's lead author Warren Kruger, Ph.D., senior faculty member at Fox Chase. "In essence, we're using Hsp70 to call a biochemical mulligan, a do-over."

"Hsp70 pulls a misfolded amino acid chain apart like a twisted rubber band and allows it to snap back into place, which we found can restore a significant percentage of proteins to working shape," Kruger says. "If this can be done in humans, it could represent a way of reducing the severity - or perhaps correcting - certain hereditary diseases, even some familial cancers."

Kruger and his colleagues are currently studying how to adapt these findings to human disease. While the study was done in a yeast model for human disease, humans possess at least nine members of the Hsp70 family of chaperones. Evidence suggests that it might be feasible to modify the chaperone environment in order to give Hsp70 better opportunities to rescue broken proteins. "The more chances we give Hsp70 proteins to try to 'fix' the output of mutant genes, the more chances are that they will succeed," Kruger says.

Very often, genetic mutations occur when errors in the DNA code substitute one amino acid for another. It is this sort of mutation that is at the center of a disease called cystathionine β-synthase (CBS) deficiency, an inherited metabolic disorder that the Kruger laboratory uses as a genetic model.

Through experiments performed by Laishram Singh, a post-doctoral fellow in the lab, Kruger learned that exposure to alcohol restored the function of a mutant human CBS protein expressed in genetically engineered yeast cells. This exposure activates heat shock proteins, like Hsp70, which help the cell respond to the shock, or damage, from stress. The sudden excess of Hsp70, in turn, had the side effect of rescuing mutated proteins in addition to those damaged by alcohol.

According to Kruger, Hsp70 works in equilibrium with another heat shock protein, Hsp26, as a sort of biochemical damage control system. While Hsp70 acts like a chaperone to restore the function of such proteins, Hsp26 targets the misfolded proteins to the proteosome, the "garbage disposal" of the cell. The two proteins, it seems, function in opposition, competing to clean up damaged proteins within cells.

The relationship between these two proteins may provide an opportunity for intervention, Kruger reasons. When Kruger and his colleagues removed the gene encoding Hsp26 from yeast, they saw a nine-fold increase in the amount of properly functioning human CBS protein. "If we can target Hsp26 and take it out of circulation, we might be able to give Hsp70 more room to operate," Kruger says.
-end-
Funding for this research comes from grants from the National Institutes of Health and the Commonwealth of Pennsylvania. An image is available at http://www.fccc.edu/images/news/research/KrugerJCB09.jpg.

Fox Chase Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.